%0 Journal Article %A Pankaj Kumar Mishra %A Natalie Bruiners %A Rahul Ukey %A Pratik Datta %A Alberta Onyuka %A Deborah Handler %A Sabiha Hussain %A William Honnen %A Sukhwinder Singh %A Valentina Guerrini %A Yue Yin %A Hannah Dewald %A Alok Choudhary %A Daniel B. Horton %A Emily S. Barrett %A Jason Roy %A Stanley H. Weiss %A Patricia Fitzgerald-Bocarsly %A Martin J. Blaser %A Jeffrey L. Carson %A Reynold A. Panettieri, Jr. %A Alfred Lardizabal %A Theresa Li-Yun Chang %A Abraham Pinter %A Maria Laura Gennaro %T Vaccination boosts protective responses and counters SARS-CoV-2-induced pathogenic memory B cells %D 2021 %R 10.1101/2021.04.11.21255153 %J medRxiv %P 2021.04.11.21255153 %X Much is to be learned about the interface between immune responses to SARS-CoV-2 infection and vaccination. We monitored immune responses specific to SARS-CoV-2 Spike Receptor-Binding-Domain (RBD) in convalescent individuals for eight months after infection diagnosis and following vaccination. Over time, neutralizing antibody responses, which are predominantly RBD specific, generally decreased, while RBD-specific memory B cells persisted. RBD-specific antibody and B cell responses to vaccination were more vigorous than those elicited by infection in the same subjects or by vaccination in infection-naïve comparators. Notably, the frequencies of double negative B memory cells, which are dysfunctional and potentially pathogenic, increased in the convalescent subjects over time. Unexpectedly, this effect was reversed by vaccination. Our work identifies a novel aspect of immune dysfunction in mild/moderate COVID-19, supports the practice of offering SARS-CoV-2 vaccination regardless of infection history, and provides a potential mechanistic explanation for the vaccination-induced reduction of “Long-COVID” symptoms.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThis is an observational, longitudinal research studyFunding StatementThis work was funded by NIH grants R01HL149450, R01HL149450-S1, U01 AI122285-S1, and UL1 TR003017.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional review board of the Rutgers New Jersey Medical School, IRB approval No. : Pro0119980237 and Pro20150001314All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are all listed in the article and available from the corresponding author upon reasonable request. %U https://www.medrxiv.org/content/medrxiv/early/2021/05/12/2021.04.11.21255153.full.pdf